title: Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study.
abstract: Insulin resistance, through numerous related disturbances in glucose and lipoprotein-lipid metabolism, is associated with an increased risk of ischemic heart disease (IHD). The purpose of the present study was to examine the relationship between increased plasma free fatty acid (FFA) concentrations, as a feature of the insulin resistance syndrome, and the risk of IHD in men. Analyses were carried out in a nested, case-control sample of men selected from a population of 2103 individuals without IHD at baseline among whom 114 developed IHD during a 5-year follow-up period. Incident IHD cases were matched with controls for age, body mass index, smoking habits and alcohol intake. Analyses were performed while excluding (88 cases and 98 controls) and including (103 cases and 99 controls) patients with type 2 diabetes. Among non-diabetic individuals, elevated plasma FFA concentrations (3rd tertile of the distribution) yielded a twofold increase in the risk of IHD (odds ratio [OR] 2.1, P=0.05) compared with lower plasma FFA levels (lowest tertile) after adjusting for non-lipid risk factors. Further adjustment for insulin, triglycerides, apolipoprotein B, HDL cholesterol and small dense LDL attenuated significantly the relationship between plasma FFA concentrations and the risk of IHD. High plasma FFA levels showed no synergism with selected features of the insulin resistance syndrome in determining the risk of IHD. Inclusion of diabetic subjects in the study did not improve FFA independent prognostic value to the risk of IHD. These results suggest that elevated plasma FFA concentrations are associated with an increased risk of IHD. However, a single fasting measurement of plasma FFA levels does not appear to improve our ability to predict IHD onset in men when information on other risk factors is considered.
authors.affiliation: Department of Food Science and Nutrition, Lipid Research Center, R-9600 CHUL Research Center, 2705 Laurier Boulevard, Ste-Foy, G1V 4G2, Quebec, Canada
authors.forename: Matteo
authors.initials: M
authors.lastname: Pirro
authors.forename: Pascale
authors.initials: P
authors.lastname: Mauriège
authors.forename: André
authors.initials: A
authors.lastname: Tchernof
authors.forename: Bernard
authors.initials: B
authors.lastname: Cantin
authors.forename: Gilles R
authors.initials: GR
authors.lastname: Dagenais
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Després
authors.forename: Benoît
authors.initials: B
authors.lastname: Lamarche
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D015992:Body Mass Index; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000737:chemistry; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood*; D016017:Odds Ratio; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol